Treatment outcome and germline predictive factors of ropeginterferon alpha‐2b in myeloproliferative neoplasm patients

Abstract

AbstractBackgroundStudies have shown that some single nucleotide polymorphisms (SNPs) could serve as excellent markers in foretelling the treatment outcome of interferon (IFN) in myeloproliferative neoplasms (MPN). However, most work originated from western countries, and data from different ethnic populations have been lacking.MethodsTo gain insights, targeted sequencing was performed to detect myeloid‐associated mutations and SNPs in eight loci across three genes (IFNL4, IFN‐γ, and inosine triphosphate pyrophosphatase [ITPA]) to explore their predictive roles in our cohort of 21 ropeginterferon alpha‐2b (ROPEG)‐treated MPN patients, among whom real‐time quantitative PCR was also performed periodically to monitor the JAK2V617F allele burden in 19 JAK2V617F‐mutated cases.ResultsELN response criteria were adopted to designate patients as good responders if they achieved complete hematological responses (CHR) within 1 year (CHR1) or attained major molecular responses (MMR), which occurred in 70% and 45% of the patients, respectively. IFNL4 and IFN‐γ gene SNPs were infrequent in our population and were thus excluded from further analysis. Two ITPA SNPs rs6051702 A>C and rs1127354 C>A were associated with an inferior CHR1 rate and MMR rate, respectively. The former seemed to be linked to grade 2 or worse hepatotoxicity as well, although the comparison was of borderline significance only (50%, vs. 6.7% in those with common haplotype, p = 0.053). Twelve patients harbored 19 additional somatic mutations in 12 genes, but the trajectory of these mutations varied considerably and was not predictive of any response.ConclusionsOverall, this study provided valuable information on the ethnics‐ and genetics‐based algorithm in the treatment of MPN.